Papers/PMID:32383748
Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial.
JAMA network open2020The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Zn(2+) — no detected effect on all-cause mortality
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×2“In post-hoc analyses, we found no statistically significant difference in mortality by zinc vs placebo study group (adjusted hazard ratio, 1.80; 95% CI, 0.88-3.65; P =.10).”
Quoted verbatim from Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial.. - Study
- RCT
- Dose
- zinc gluconate 15 mg elemental zinc daily (men) or 12 mg (women) for 18 months
- Population
- Antiretroviral-naive adults with HIV and heavy alcohol use in St Petersburg, Russia; sucrose-plus-riboflavin placebo, riboflavin given to both arms
Effect 1.8 hazard ratio, 95% CI 0.88 to 3.65
Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial.2020PMID:32383748Permalink